2025-12-21 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the data you provided, broken down into the requested sections:

**0) Report in English:**

**1) Return Rate Comparison:**

*   **Ticker:** JNJ
*   **Company Overview:** Johnson & Johnson is a multinational corporation that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.
*   **JNJ Cumulative Return:** 59.05%
*   **S&P 500 (VOO) Cumulative Return:** 100.88%
*   **Divergence:** -38.5 (Divergence range (max: 16.6, min: -65.5, current: -38.5, relative divergence: 32.9))

**Analysis:** JNJ has significantly underperformed the S&P 500 over the tracked period.  The divergence of -38.5% means JNJ's return is 38.5 percentage points lower than the S&P 500's. The relative divergence of 32.9 suggests the current divergence is in the lower end of its historical divergence range, meaning it is closer to the minimum divergence observed than the maximum.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|-------|--------|------|--------|
| 2015-2017  | 26.0%  | 66.8% | -2.0%  | -0.1 | 336.6  |
| 2016-2018  | 14.0%  | 10.7% | -1.0%  | 0.1  | 310.9  |
| 2017-2019  | 20.0%  | 71.5% | -2.0%  | 0.4  | 351.4  |
| 2018-2020  | 19.0%  | 79.2% | -4.0%  | 0.4  | 379.2  |
| 2019-2021  | 33.0%  | 79.2% | -14.0% | 0.5  | 412.2  |
| 2020-2022  | 8.0%   | 79.6% | 9.0%   | 0.4  | 425.6  |
| 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3  | 377.6  |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3  | 348.4  |
| 2023-2025  | 30.0%  | 79.6% | -35.0% | 0.1  | 497.2  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows a wide range of returns.
*   **MDD:** Maximum Drawdown (MDD) is high, suggesting significant risk.
*   **Alpha:**  Alpha is mostly negative, indicating underperformance relative to the benchmark (risk-adjusted).  There is one period of positive Alpha (2020-2022), suggesting outperformance.
*   **Beta:** Beta is generally low (around 0.1 to 0.5), indicating JNJ is less volatile than the market.
*   **Cap(B):** The market capitalization in Billions.

**2) Recent Stock Price Fluctuations:**

*   **Close:** 206.37
*   **Previous Close:** 208.31
*   **Change:** -0.93
*   **5-day SMA:** 209.70
*   **20-day SMA:** 206.46
*   **60-day SMA:** 195.83

**Analysis:** The stock price has recently decreased. The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA. This suggests a recent short-term downtrend (price below 5 day moving average), but the 20-day is higher than 60-day average, indicating overall uptrend.

**3) RSI, PPO, and Expected Return:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment Recommended)
*   **RSI:** 53.23
*   **PPO:** -0.19
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)
*   **Recent (20 days) relative divergence change:** 10.2 (+): 단기상승 (Short-term rise)
*   **Expected Return (%):** -48.4

**Analysis:**

*   **MRI:** The MRI suggests a medium investment recommendation.
*   **RSI:** The RSI of 53.23 is neutral, indicating neither overbought nor oversold conditions.
*   **PPO:** A negative PPO (-0.19) suggests that the short-term moving average is below the long-term moving average, which can be a bearish signal.
*   **Hybrid Signal:** The signal suggests buying, which is an positive signal.
*   **Recent Divergence Change:** The recent increase in relative divergence is a positive sign for short-term performance.
*   **Expected Return:** The extremely negative expected return of -48.4% is alarming and suggests significant concerns about JNJ's future performance relative to the S&P 500.

**4) Recent News & Significant Events:**

*   **[2025-12-04]** "Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note"
*   **[2025-12-20]** "Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast"
*   **[2025-11-21]** "1 Reason Why Shares of Johnson & Johnson Are Surging This Month"
*   **[2025-12-20]** "54,803 Shares in Johnson & Johnson $JNJ Bought by NatWest Group plc"
*   **[2025-12-16]** "$JNJ stock is down 3% today. Here's what we see in our data."
*   **[2025-12-18]** "Johnson & Johnson (JNJ) Stock Forecast: Key Levels And Resistance Levels"

**Analysis:** The news headlines present a mixed picture. There are concerns about stock drops, talc verdicts, and drug pricing pressure.  However, there is also news of a surge in share price and a significant purchase by NatWest Group.  The overall sentiment appears cautiously negative, with potential headwinds.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 2.16 (~Buy)
*   **Opinions:** 24
*   **Target Price (avg/high/low):** 209.29 / 240.00 / 155.00
*   **Recent Rating Changes:** Not provided.

**Analysis:**  Analysts, on average, have a "Buy" rating on JNJ, with a target price slightly above the current price. However, the wide range in target prices (155.00 to 240.00) indicates uncertainty and differing opinions on the stock's potential.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-10-22 | 2.14  | 23.99 B$   |
| 2025-07-24 | 2.3   | 23.74 B$   |
| 2025-04-23 | 4.57  | 21.89 B$   |
| 2024-10-23 | 1.12  | 22.47 B$   |
| 2025-10-22 | 1.12  | 22.47 B$   |

**Analysis:**

*   **Revenue:**  Revenue appears to be increasing over the last few quarters.
*   **EPS:** EPS is volatile. There's one large EPS, but the others are in similar range.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $23.99B   | 69.56%        |
| 2025-06-30   | $23.74B   | 67.87%        |
| 2025-03-31   | $21.89B   | 66.40%        |
| 2024-12-31   | $22.52B   | 68.35%        |
| 2024-09-30   | $22.47B   | 69.01%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30   | $79.28B   | 6.50% |
| 2025-06-30   | $78.47B   | 7.06% |
| 2025-03-31   | $78.11B   | 14.08% |
| 2024-12-31   | $71.49B   | 4.80% |
| 2024-09-30   | $70.16B   | 3.84% |

**Analysis:**

*   **Revenue:** Revenue is generally increasing.
*   **Profit Margin:**  Profit margins are consistently high, indicating good profitability.
*   **Equity:** Equity is increasing, indicating growth in the company's net worth.
*   **ROE:** ROE is volatile.

**7) Comprehensive Analysis (Summary):**

Johnson & Johnson (JNJ) presents a mixed investment picture.

*   **Underperformance:**  JNJ has significantly underperformed the S&P 500.
*   **Volatility:** High Maximum Drawdown suggests significant risk.
*   **Technicals:** Recent price action suggests a possible short-term downward, but overall uptrend.
*   **MRI:** The MRI indicates a medium investment recommendation, but the negative expected return should be a major red flag.
*   **News:** Recent news headlines are a mixed bag, highlighting both positive and negative factors.
*   **Analyst Ratings:** Analysts, on average, rate the stock as a "Buy," but the wide range in target prices reflects uncertainty.
*   **Financials:** JNJ has strong financials, with increasing revenue, high profit margins, and growing equity. The variable ROE may need a deeper look.

**Overall Recommendation:**

While JNJ has solid financials and is generally considered a stable, less volatile stock, the significant underperformance compared to the S&P 500 and the negative expected return are concerning. Further investigation is warranted to understand the drivers behind this underperformance and the negative outlook.  Based on this data alone, a cautious approach is advised. The news about potential legal liabilities (talc) and drug pricing pressures needs to be carefully considered. Depending on one's risk tolerance, further investigation of the cause of negative Alpha and expected return may be warranted.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.